BB Biotech’s Exelixis EXEL Stock Holding History

BB Biotech’s Portfolio EXEL Stock Details EXEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$67.5M	Hold	2,835,000	–	–	1.7%	19
2018 Q4	$55.8M	Buy	2,835,000 +50,000	+2%	+$891K	1.79%	20
2018 Q3	$49.4M	Buy	2,785,000 +1,725,000	+163%	+$33.6M	1.31%	24
2018 Q2	$22.8M	Buy	+1,060,000	New	+$21.9M	0.66%	27

Other funds holding EXEL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BB Biotech's EXEL Position: Q1 2019 in Review

BB Biotech held its Exelixis (EXEL) position steady in Q1 2019 at 2,835,000 shares worth $67.5M. The position accounts for 1.7% of the portfolio, ranked #19.

BB Biotech first reported a position in EXEL in Q2 2018 and has held it in 4 quarters since. 378 funds tracked by Wall St. Rank hold EXEL as of Q1 2019.

BB Biotech held 2,835,000 shares of Exelixis worth $67.5M as of Q1 2019.
BB Biotech left its Exelixis share count unchanged in Q1 2019.
Exelixis made up 1.7% of BB Biotech's portfolio in Q1 2019, its #19 holding.
BB Biotech first reported a position in Exelixis in Q2 2018 and has held it in 4 quarters since.
378 funds tracked by Wall St. Rank held Exelixis as of Q1 2019.

Based on BB Biotech's 13F filing for Q1 2019, filed 13 May 2019.